•
De Benedittis G, Massei R: Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. J Neurosurg Sci. 1985 Jul-Sep;29(3):239-48. Pubmed•
Birdsall TC: 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998 Aug;3(4):271-80. Pubmed•
Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M: Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats. Jpn J Pharmacol. 1982 Oct;32(5):803-11. Pubmed•
Bouchard S, Roberge AG: Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat. Can J Biochem. 1979 Jul;57(7):1014-8. Pubmed•
Amamoto T, Sarai K: On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression. Hiroshima J Med Sci. 1976 Sep;25(2-3):135-40. Pubmed•
Turner EH, Blackwell AD: 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses. 2005;65(1):138-44. Pubmed•
Shaw K, Turner J, Del Mar C: Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;(1):CD003198. Pubmed•
Magnussen I, Jensen TS, Rand JH, Van Woert MH: Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man. Acta Pharmacol Toxicol (Copenh). 1981 Sep;49(3):184-9. Pubmed•
Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V: Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9. Pubmed•
Birdsall TC: 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998 Aug;3(4):271-80. Pubmed•
Nakatani Y, Sato-Suzuki I, Tsujino N, Nakasato A, Seki Y, Fumoto M, Arita H: Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur J Neurosci. 2008 May;27(9):2466-72. Pubmed•
Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK: Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980 Oct 2;303(14):782-7. Pubmed•
Trouillas P, Serratrice G, Laplane D, Rascol A, Augustin P, Barroche G, Clanet M, Degos CF, Desnuelle C, Dumas R, et al.: Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol. 1995 May;52(5):456-60. Pubmed• Gartside, S., et al.: Eur. J. Pharmacol., 179, 103 (1990)
• ; Schruers, K., et al.: Psychiatry Res., 113, 237 (1990)
• Gijsman, H., et al.: J. Clin. Psychopharmacol., 22, 183 (1990)
• Iriuchijima, S. et al., Agric. Biol. Chem., 1978, 42, 843, (synth, deriv)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, HOA575; HOA600; HON800; HOO000; HOO100
• Morris, A.J. et al., J.O.C., 1957, 22, 306, (resoln, abs config)
• Van Praag, H.M., Neuropharmacology, 1983, 22, 433, (rev)
• Irie, K. et al., Chem. Pharm. Bull., 1984, 32, 2126, (synth)
• Aldrich Library of 13C and 1H FT NMR Spectra, 1992, 3, 146B, (nmr)
• Witkop, B. et al., J.A.C.S., 1954, 76, 5579, (synth)
• Biochem. Prep., 1962, 9, 92, (synth)
• Tyler, V.E. et al., J. Pharm. Sci., 1964, 53, 462, (isol)
• Wakahara, A. et al., Bull. Chem. Soc. Jpn., 1973, 46, 2475, (cryst struct)
• Francis, P. et al., Biomed. Mass Spectrom., 1980, 7, 294, (ms, deriv)
• Frahn, J.L. et al., Aust. J. Chem., 1974, 27, 1367, (synth, deriv)
• Aldrich Library of FT-IR Spectra, 1st edn., 1985, 2, 673C; 673D, (ir)
• Bell, E.A. et al., Nature (London), 1966, 210, 529, (isol)
• For routes to 2-bromo-5-hydroxytryptophan derivatives, see: Synthesis, 28 (1996).
有害性 (Xn)
